{"id":"emd-72000","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"15-25%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Rash"},{"rate":"1-5%","effect":"Pneumonitis"}]},"_chembl":{"chemblId":"CHEMBL2109417","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by blocking the PD-L1 protein, which is involved in the immune system's regulation of cancer cell growth. This allows the immune system to recognize and attack cancer cells more effectively.","oneSentence":"EMD 72000 is a monoclonal antibody targeting PD-L1.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:37:11.873Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, PD-L1 positive"},{"name":"Head and neck squamous cell carcinoma"}]},"trialDetails":[{"nctId":"NCT06857279","phase":"PHASE2","title":"A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-04-22","conditions":"Carcinoma of Head and/or Neck","enrollment":167},{"nctId":"NCT06735391","phase":"PHASE3","title":"A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations","status":"RECRUITING","sponsor":"Shanghai JMT-Bio Inc.","startDate":"2024-10-23","conditions":"Locally Advanced or Metastatic Non-squamous NSCLC, Harboring EGFR Sensitive Mutations NSCLC, Previously Untreated Systematically NSCLC","enrollment":516},{"nctId":"NCT05221658","phase":"PHASE2","title":"A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-08-25","conditions":"ESCC or Esophageal Adenosquamous Carcinoma","enrollment":60},{"nctId":"NCT05215925","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2023-02-01","conditions":"HLX07, nsqNSCLC, High EGFR Expression","enrollment":60},{"nctId":"NCT05238363","phase":"PHASE2","title":"The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-06-15","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":20},{"nctId":"NCT05360368","phase":"PHASE1","title":"HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2023-03-30","conditions":"Solid Tumor","enrollment":24},{"nctId":"NCT05354700","phase":"PHASE2","title":"A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2023-03-29","conditions":"Small-cell Lung Cancer","enrollment":20},{"nctId":"NCT05290220","phase":"PHASE2","title":"HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-08-01","conditions":"Advanced Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT05239650","phase":"PHASE2","title":"Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2022-07-15","conditions":"CRC","enrollment":50},{"nctId":"NCT05246982","phase":"PHASE2","title":"HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Henlius Biotech","startDate":"2022-03-23","conditions":"Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)","enrollment":40},{"nctId":"NCT00215644","phase":"PHASE2","title":"Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2005-08-31","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":72},{"nctId":"NCT00111839","phase":"PHASE2","title":"Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2005-05-31","conditions":"Lung Cancer, Non Small Cell Lung Carcinoma","enrollment":150},{"nctId":"NCT00073541","phase":"PHASE2","title":"A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2003-04","conditions":"Ovarian Cancer","enrollment":38},{"nctId":"NCT00113581","phase":"PHASE1","title":"Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2002-10","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"EMD 72000","genericName":"EMD 72000","companyName":"EMD Serono","companyId":"emd-serono","modality":"Small molecule","firstApprovalDate":"","aiSummary":"EMD 72000 is a monoclonal antibody targeting PD-L1. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}